Searchable abstracts of presentations at key conferences in endocrinology

ea0081ep173 | Calcium and Bone | ECE2022

Palovarotene for the treatment of fibrodysplasia ossificans progressiva: methodology of the phase III open-label PIVOINE rollover trial

Artyomenko Alexander , Houchard Aude , Zemam Azzeddine

Objectives: Fibrodysplasia ossificans progressiva (FOP) is an ultra-rare genetic disorder characterized by heterotopic ossification (HO) and progressive restriction of mobility. To date, no approved disease-modifying treatments for FOP exist, but interim phase III trial (NCT03312634) results suggest marked efficacy for palovarotene (PVO).1 Here, we describe methodology of the PIVOINE trial (NCT05027802) designed to allow treatment continuity and further evaluation o...

ea0081oc4.5 | Oral Communications 4: Pituitary and Neuroendocrinology 1 | ECE2022

Real-world injection experience and use of independent injection among patients using lanreotide autogel/depot (LAN) prefilled syringe or octreotide long-acting release (OCT) to treat acromegaly or neuroendocrine tumors (NETs): international PRESTO 2 survey

Webb Susan , O'Toole Dermot , Kunz Pamela , Houchard Aude , Boiziau Sandra , Ribeiro-Oliveira Antonio , Prebtani Ally

Introduction: Long-acting (LA) somatostatin analog (SSA) therapy is a common first-line medical treatment for acromegaly and NETs. There are limited real-world data on patients’ injection experience with the latest LA SSA devices/formulations.Aims: To compare the injection experience of patients with acromegaly or NETs who were receiving treatment with LAN prefilled syringe vs OCT syringe.Methods: A 2021 e-survey of adults wit...

ea0090ep721 | Pituitary and Neuroendocrinology | ECE2023

An international, simulated-use study assessing nurses’ preferences between two lanreotide syringes (Somatuline Autogel vs Pharmathen) for treatment of neuroendocrine tumours (NETs) and/or acromegaly: PRESTO 3

Ferone Diego , Martin Wendy , Williams Jessica , Houchard Aude , Pommie Christelle , Ribeiro-Oliveira Antonio , Grossman Ashley B

Introduction/Background: Patients with NETs and acromegaly are commonly treated with somatostatin analogues (SSAs), such as octreotide and lanreotide depot formulations. The Pharmathen syringe is now available in several European countries and the USA for lanreotide depot injection. When using SSAs, confidence in and ease of use with syringes is important for decision-making in long-term therapy.Aims: PRESTO 3 compared nurses’ preference for the Som...

ea0068oc1 | Abstracts | UKINETS2019

Longitudinal biomarker changes during treatment of functional midgut neuroendocrine tumours with lanreotide autogel: CALM-NET study results

Shah Tahir , Caplin Martyn , Khan Mohid S , Houchard Aude , Higgs Kate , Meyer Tim

Background: CALM-NET (EudraCT 2013-002194-22; NCT02075606), a prospective, exploratory study, evaluated enumeration of pre-treatment circulating tumour cells as a predictor of symptomatic response to lanreotide autogel (LAN) in patients with functional midgut neuroendocrine tumours (NETs). Here, we describe the effect of LAN on biomarkers.Methods: Patients, ≥18 years, with functional, well- or moderately-differentiated midgut NETs were treated with...

ea0063p731 | Pituitary and Neuroendocrinology 2 | ECE2019

Therapeutic decisions in acromegaly according to disease control in patients with acromegaly with or without prior treatment: data from baseline analysis of the SAGIT® validation study

Giustina Andrea , Bronstein Marcello , Chanson Philippe , Petersenn Stephan , Casanueva Felipe , Sert Caroline , Houchard Aude , Melmed Shlomo

Background: The SAGIT® instrument, designed to assist clinicians in staging and managing acromegaly, is undergoing validation. A descriptive analysis of SAGIT Validation study baseline data revealed discrepancies between investigator-evaluated disease-control status, disease activity, hormonal control, and treatment decisions in acromegaly.Objective: To describe the baseline characteristics of patients in the SAGIT® valida...

ea0049gp191 | Pituitary & endocrine Tumours | ECE2017

GH and IGF-1 levels at 12 weeks predict long-term responses to lanreotide Autogel in treatment-naïve acromegalic patients: post-hoc analyses from the PRIMARYS study

Caron Philippe , Petersenn Stephan , Houchard Aude , Sert Caroline , Bevan John S

Background: In PRIMARYS, lanreotide Autogel (LAN) 120 mg/28 days reduced tumour volume (TV), and GH/IGF-1 levels in patients with GH-secreting macroadenomas. In post-hoc analyses, we investigated predictive factors for treatment responses.Methods: PRIMARYS, a 48-week, international, open-label study, involved 90 treatment-naïve patients with GH-secreting macroadenomas receiving LAN. Factors predictive for hormonal control (HC; GH ≤2.5...

ea0041gp161 | Pituitary - Clinical (1) | ECE2016

Evaluation of MRI T2-signal intensities of GH-secreting pituitary macroadenoma in treatment-naïve acromegalic patients receiving primary treatment with lanreotide autogel (LAN-ATG) 120 mg

Caron Philippe , Riviere Louis-David , Houchard Aude , Sert Caroline , Bonneville Fabrice

Introduction: Pituitary MRI T2-signal intensity may be associated with the response to somatostatin analogue therapy in acromegalic patients. Here, we explore how best to evaluate MRI T2-signal intensity of GH-secreting pituitary macroadenoma using data from the PRIMARYS study (NCT00690898; EudraCT2007-000155-34).Methods: PRIMARYS assessed tumour volume reduction (TVR) on MRI in treatment-naïve acromegalic patients with GH-secreting pituitary macroa...

ea0041ep873 | Pituitary - Clinical | ECE2016

Comorbidities and treatment patterns among patients with acromegaly in Sweden : a register-linkage population-based study

Lesen Eva , Granfeldt Daniel , Houchard Aude , Dinet Jerome , Berthon Anthony , Bjorholt Ingela , Johannsson Gudmundur

Introduction: Treatment of patients with acromegaly is complex, including surgery, pharmacotherapy and radiotherapy. The objective was to describe comorbidities and treatment patterns among patients with acromegaly in Sweden.Methods: Population-based study including all patients with a first diagnosis of acromegaly due to a pituitary adenoma in Sweden between 1 Jul 2005 and 31 Dec 2013. Data was obtained via linkage of the National Patient Register, Swed...

ea0081p411 | Pituitary and Neuroendocrinology | ECE2022

Independent injection vs healthcare-setting administration of somatostatin analogues: A systematic literature review

Luiz Boguszewski Cesar , Korbonits Marta , Artignan Audrey , Martin Garcia Almudena , Houchard Aude , Ribeiro-Oliveira Antonio , W de Herder Wouter

Background: A systematic literature review (SLR) was conducted to assess the use of independent injections (self/partner/home-administered) as an alternative to healthcare-setting injections for chronic diseases. The primary objective was to identify studies reporting on independent injection of somatostatin analogues (SSAs). Comparative evidence on independent injection of other medications was examined as a secondary objective.Methods: MEDLINE/Embase/t...

ea0081p432 | Pituitary and Neuroendocrinology | ECE2022

A systematic literature review to evaluate extended dosing intervals in the pharmacological management of acromegaly

Fleseriu Maria , Zhang Zhaoyun , Hanman Kate , Haria Keval , Houchard Aude , Khawaja Sheila , Ribeiro-Oliveira Antonio , Gadelha Monica

Background: Acromegaly is a rare disorder characterized by excess growth hormone (GH) and insulin-like growth factor 1 (IGF-1). Extended dosing intervals (EDIs) of pharmacological treatments may reduce patient burden and costs compared with standard dosing. This systematic literature review (SLR) investigated treatment of acromegaly at EDIs.Methods: MEDLINE/Embase/the Cochrane Library (2001–June 2021) and key congresses (2018–2021) were searche...